Appreciation of the Possibility of Dosing Neopterin in Eye Liquids. Pilot Study of Neopterin Dosage in Eye Liquids.
| Registry | NCT03497481, acronym CHA |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 20 (Actual) |
| Sponsor | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (Other); collaborators: Hospices Civils de Lyon |
| Conditions | Cataract |
| Interventions | Samples (Biological) |
| Dates | start 2018-06-22, primary completion 2019-01-25, completion 2019-01-25, first posted 2018-04-13, last updated 2022-10-26 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Cataract All trials of Samples
The purpose of the study is to determine whether neopterin can be dosed in the fluid of the eye's anterior chamber for patient with non-inflammatory and non-infectious ophthalmic pathology.
The study will be explained to subjects who are about to undergo ophthalmologic surgery. They will sign an informed consent and be included in the study. Urine sample will be collected specifically for the study. Eye's anterior chamber fluid will also be collected during the surgery as it is the usual practice (the sample is used for the neopterin dosage instead of being thrown away).
These samples will be centrifuged, frozen in a -80° C freezer. At the end of the study, all the samples will be sent to the central Lab for the neopterin dosage analysis. Results will be communicated to the principal investigator afterward.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Neopterin Dosage | Biological: Samples | Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Age ≥ 18 years-old * Non inflammatory or non infectious ophthalmic pathology requiring puncture of eye's anterior chamber fluid. * Minimum of 200 microliter sample * Immunocompetent subjects * Signed and dated informed consent * Samples management in accordance with the pre-analytical conditions specified in the protocol Non-inclusion criteria: * Age < 18 years-old * Subjects treated with intraocular corticoids, antibiotics or anti-inflammatory, locally or in systemic injection, prior to inclusion. Exclusion Criteria: * Subjects who exercised his right of withdrawal * Study suspended on principal investigator, sponsor or health authorities' demand. * Deceased subjects
| Facility | City | Country | Status |
|---|---|---|---|
| Centre Hospitalier Intercommunal Toulon La Seyne sur Mer | Toulon, Var | France |